,
Zitvogel Acquisition of data (provided animals, acquired and managed patients, provided facilities ,
Management of metastatic melanoma, Semin Oncol, vol.34, pp.532-577, 2007. ,
Duration of survival for disseminated malignant melanoma: results of a meta-analysis, Melanoma Res, vol.10, pp.81-92, 2000. ,
Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study, J Clin Oncol, vol.22, pp.2101-2108, 2004. ,
Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma, J Clin Oncol, vol.18, pp.158-66, 2000. ,
Mutations of the BRAF gene in human cancer, Nature, vol.417, pp.949-54, 2002. ,
Sorafenib in advanced melanoma: a phase II randomised discontinuation trial analysis, Br J Cancer, vol.95, pp.581-587, 2006. ,
Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma, J Clin Oncol, vol.31, pp.373-382, 2013. ,
Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma, J Clin Oncol, vol.27, pp.2823-2853, 2009. ,
Phase II trial of temozolomide and sorafenib in advanced melanoma patients with or without brain metastases, Clin Cancer Res, vol.15, pp.7711-7719, 2009. ,
Improved survival with ipilimumab in patients with metastatic melanoma, N Engl J Med, vol.363, pp.711-734, 2010. ,
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma, N Engl J Med, vol.364, pp.2517-2543, 2011. ,
Van den Eynde BJ, van der Bruggen P. Human T cell responses against melanoma, Annu Rev Immunol, vol.24, pp.175-208, 2006. ,
A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer, Clin Cancer Res, vol.12, pp.1260-1269, 2006. ,
Cancer vaccines: moving beyond current paradigms, Clin Cancer Res, vol.13, pp.3776-82, 2007. ,
The anticancer immune response: indispensable for therapeutic success?, J Clin Invest, vol.118, pp.1991-2001, 2008. ,
Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors, Nat Med, vol.15, pp.1170-1178, 2009. ,
URL : https://hal.archives-ouvertes.fr/hal-00419823
Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice, J Clin Invest, vol.120, pp.1111-1135, 2010. ,
Pathologic complete response to neoadjuvant chemotherapy of breast carcinoma is associated with the disappearance of tumor-infiltrating foxp3 þ regulatory T cells, Clin Cancer Res, vol.14, pp.2413-2433, 2008. ,
5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity, Cancer Res, vol.70, pp.3052-61, 2010. ,
Progressive upregulation of PD-1 in primary and metastatic melanomas associated with blunted TCR signaling in infiltrating T lymphocytes, J Invest Dermatol, vol.131, pp.1300-1307, 2011. ,
Adaptive immunity maintains occult cancer in an equilibrium state, Nature, vol.450, pp.903-910, 2007. ,
Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines, J Exp Med, vol.183, pp.87-97, 1996. ,
Loss of nonclassical MHC molecules MIC-A/B expression during progression of uveal melanoma, Br J Cancer, vol.91, pp.1495-1504, 2004. ,
Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity, Nature, vol.413, pp.165-71, 2001. ,
NKG2D function protects the host from tumor initiation, J Exp Med, vol.202, pp.583-591, 2005. ,
Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma, Int J Cancer, vol.117, pp.596-604, 2005. ,
Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming, Proc Natl Acad Sci U S A, vol.104, pp.8947-52, 2007. ,
Analysis of relative gene expression data using real-time quantitative PCR and the 2(Àdelta delta C(T)) method, Methods, vol.25, pp.402-410, 2001. ,
Increased frequency of nonconventional double positive CD4CD8 alphabeta T cells in human breast pleural effusions, Int J Cancer, vol.125, pp.374-80, 2009. ,
Activating NK-cell receptors co-stimulate CD4(þ)CD28(À) T cells in patients with rheumatoid arthritis, Eur J Immunol, vol.40, pp.378-87, 2010. ,
Coordinated induction by IL15 of a TCR-independent NKG2D signaling pathway converts CTL into lymphokine-activated killer cells in celiac disease, Immunity, vol.21, pp.357-66, 2004. ,
Reduced immunosuppressive properties of axitinib in comparison with other tyrosine kinase inhibitors, J Biol Chem, vol.288, pp.16334-16381, 2013. ,
NKG2D-mediated antitumor activity by tumor-infiltrating lymphocytes and antigen-specific T-cell clones isolated from melanoma patients, Clin Cancer Res, vol.13, pp.7459-68, 2007. ,
Fas-ligand-mediated paracrine T cell regulation by the receptor NKG2D in tumor immunity, Nat Immunol, vol.7, pp.755-62, 2006. ,
Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation, Nature, vol.419, pp.734-742, 2002. ,
Normally occurring NKG2D þ CD4 þ T cells are immunosuppressive and inversely correlated with disease activity in juvenile-onset lupus, J Exp Med, vol.206, pp.793-805, 2009. ,
Expansion of circulating NKG2Dþ effector memory T-cells and expression of NKG2D-ligand MIC in granulomaous lesions in Wegener's granulomatosis, Clin Immunol, vol.127, pp.144-50, 2008. ,
Peripheral blood and granuloma CD4(þ)CD28(À) T cells are a major source of interferon-gamma and tumor necrosis factor-alpha in Wegener's granulomatosis, Am J Pathol, vol.160, pp.1717-1741, 2002. ,
Stimulation of T cell autoreactivity by anomalous expression of NKG2D and its MIC ligands in rheumatoid arthritis, Proc Natl Acad Sci U S A, vol.100, pp.9452-9459, 2003. ,
CD4 þ NKG2D þ T cells in Crohn's disease mediate inflammatory and cytotoxic responses through MICA interactions, Gastroenterology, vol.132, pp.2346-58, 2007. ,
NKG2D receptors induced by IL-15 costimulate CD28-negative effector CTL in the tissue microenvironment, J Immunol, vol.167, pp.5527-5557, 2001. ,
Double positive CD4CD8 alphabeta T cells: a new tumor-reactive population in human melanomas, PLoS ONE, vol.5, p.8437, 2010. ,
Treatment of metastatic melanoma with autologous CD4 þ T cells against NY-ESO-1, N Engl J Med, vol.358, pp.2698-703, 2008. ,
Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm, Nat Immunol, vol.11, pp.889-96, 2010. ,
Naive tumor-specific CD4(þ) T cells differentiated in vivo eradicate established melanoma, J Exp Med, vol.207, pp.651-67, 2010. ,
Critical role of IL-15-IL-15R for antigen-presenting cell functions in the innate immune response, Nat Immunol, vol.2, pp.1138-1181, 2001. ,
Interleukin-15 in gene therapy of cancer, Curr Gene Ther, vol.13, pp.15-30, 2013. ,